RNA polymerase III subunit GLGenealiases: RPC32HOM · SOFM · flj32422
Q-omics provides the consensus-scored POLR3GL profile across patient tissues and cancer cell-line models. POLR3GL expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, POLR3GL is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, POLR3GL RNA expression shows 19,319 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, KIRC, and ACC as cancer lineages where POLR3GL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR3GL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR3GL survival associations across molecular data types. POLR3GL RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR3GL RNA expression–survival associations across cancer types. High POLR3GL expression shows unfavorable associations in ACC, KIRP and LAML, but favorable associations in BRCA, KIRC and CESC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for POLR3GL RNA expression.
This table summarizes POLR3GL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for POLR3GL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR3GL shows lower tumor expression in KICH, THCA, LUSC and UCEC and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher POLR3GL RNA expression in tumor versus normal tissue (log2 FC = +0.550, t-test p < 0.001).
This table shows molecular features associated with POLR3GL in patient tissues and cancer cell lines. In patient samples, POLR3GL shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR3GL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
